RHYTHM PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $189.8 | $130.1 | $77.4 | $23.6 | $3.2 |
| Operating income | -$192.0 | -$265.5 | -$184.4 | -$179.2 | -$170.1 |
| Net income | -$196.5 | -$260.6 | -$184.7 | -$181.1 | -$69.6 |
| Cash Flow Statement | |||||
| Free cash flow | -$116.6 | -$113.9 | -$136.2 | -$173.7 | -$146.4 |
Shares outstanding 68.9M · Free float 88.7%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.
Coverage
October 14, 2026
Theme Survey
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
June 15, 2026
Earnings Digest
Nuvei to Acquire Payoneer for $2.75 Billion